Assenagon Asset Management S.A. Invests $4.20 Million in USANA Health Sciences, Inc. (USNA)

Assenagon Asset Management S.A. purchased a new stake in USANA Health Sciences, Inc. (NYSE:USNA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 34,867 shares of the company’s stock, valued at approximately $4,203,000. Assenagon Asset Management S.A. owned 0.14% of USANA Health Sciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co. NY raised its stake in shares of USANA Health Sciences by 16.1% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 4,482 shares of the company’s stock valued at $517,000 after purchasing an additional 623 shares during the period. United Services Automobile Association raised its stake in shares of USANA Health Sciences by 9.9% in the 2nd quarter. United Services Automobile Association now owns 6,972 shares of the company’s stock valued at $804,000 after purchasing an additional 630 shares during the period. WINTON GROUP Ltd raised its stake in shares of USANA Health Sciences by 9.5% in the 2nd quarter. WINTON GROUP Ltd now owns 8,425 shares of the company’s stock valued at $971,000 after purchasing an additional 733 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of USANA Health Sciences by 30.6% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 3,582 shares of the company’s stock valued at $413,000 after purchasing an additional 840 shares during the period. Finally, NEXT Financial Group Inc acquired a new stake in shares of USANA Health Sciences in the 3rd quarter valued at about $121,000. 51.50% of the stock is currently owned by hedge funds and other institutional investors.

USNA opened at $112.59 on Friday. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of 22.98 and a beta of 0.80. USANA Health Sciences, Inc. has a 1 year low of $64.20 and a 1 year high of $137.95.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, October 23rd. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The business had revenue of $296.80 million for the quarter, compared to the consensus estimate of $289.54 million. USANA Health Sciences had a return on equity of 30.37% and a net margin of 7.57%. USANA Health Sciences’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.03 earnings per share. Equities research analysts forecast that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current fiscal year.

USANA Health Sciences announced that its board has initiated a share repurchase plan on Tuesday, October 23rd that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 5.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Several analysts have issued reports on USNA shares. Pivotal Research reissued a “hold” rating and issued a $135.00 price target on shares of USANA Health Sciences in a research note on Wednesday, July 25th. Sidoti raised USANA Health Sciences from a “neutral” rating to a “buy” rating in a research note on Thursday, October 25th.

In related news, insider Robert A. Sinnott sold 14,741 shares of USANA Health Sciences stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $129.05, for a total value of $1,902,326.05. Following the sale, the insider now owns 7,211 shares of the company’s stock, valued at $930,579.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Myron W. Wentz sold 25,464 shares of USANA Health Sciences stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $114.36, for a total value of $2,912,063.04. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 19,117 shares of company stock worth $1,349,965 and sold 693,981 shares worth $87,976,534. 53.20% of the stock is currently owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Why is the conference call important?

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply